Life Buzz News

SGLT2i Use Linked to Lower Risk for Neurodegenerative Disease in T2DM


SGLT2i Use Linked to Lower Risk for Neurodegenerative Disease in T2DM

(HealthDay News) -- For patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with reduced risks for incident dementia and Parkinson disease (PD), according to a study published online in Neurology.

Hae Kyung Kim, MD, from the Yonsei University College of Medicine in Seoul, South Korea, and colleagues examined the association of SGLT2i use with risks for incident dementia and PD in a retrospective cohort study of 1,348,362 participants (aged 40 years and older) with type 2 diabetes who started antidiabetic drugs from 2014 to 2019. A cohort of 358,862 participants was included after propensity score matching (1:1 ratio for SGLT2i to other oral antidiabetic drugs [OADs]).

The researchers identified 6837 incident dementia or PD events. In terms of the individual end points, SGLT2i use was associated with a reduced risk for Alzheimer disease (AD), vascular dementia (VaD), and PD (adjusted hazard ratios, 0.81, 0.69, and 0.80, respectively), with a six-month drug use lag period. Compared with use of other OADs, SGLT2i use was also associated with a reduced risk for all-cause dementia and for all-cause dementia and PD (adjusted hazard ratios, 0.79 and 0.78, respectively). Sex, Charlson Comorbidity Index, diabetic complications, comorbidities, and medications did not affect the association between SGLT2i use and the reduced risk for neurodegenerative disease. Results were generally consistent in a sensitivity analysis further adjusting for bioclinical variables from health screening tests.

"These findings suggest that SGLT2is may offer neurologic benefits among patients with type 2 diabetes, although additional studies are required to validate the long-term stability of these observations," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

References:

Kim HK, Biessels GJ, Yu MH, et al. SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes. Neurology. 2024 Oct 22;103(8):e209805. doi:10.1212/WNL.0000000000209805

Previous articleNext article

POPULAR CATEGORY

corporate

8014

tech

9118

entertainment

9698

research

4322

misc

10344

wellness

7533

athletics

10195